IPO

Cemtrex secures $2M for acquisitions, but a 15% stock drop and massive shareholder dilution reveal the high price of its ambitious growth strategy.

With a doubled ETH treasury and 'Synthetic Mining' yielding up to 100%, is Republic Technologies creating the blueprint for Web3 corporate finance?

A new $50M fund says the old VC playbook is broken. We analyze if its AI-first model offers superior returns or is just a high-stakes bet on the future.

From spreadsheets to algorithms, RedCloud aims to overhaul the $14.6T FMCG market with AI. A financial turnaround now fuels its global expansion.

Streamex's $12.2M stake in Empress Royalty isn't just a purchase; it's a blueprint for tokenizing real-world assets and reshaping commodity markets.

MMTEC dodged delisting, but a one-year Nasdaq monitor and a history of reverse splits raise questions about its long-term viability on US exchanges.

An animation streaming firm is building a massive AI supercomputer in Malaysia. Is it a visionary pivot or a high-stakes bet beyond its expertise?

Scienjoy's launch of AI Vista Live! in Dubai is more than a tech debut; it's a strategic play in a $200B digital human market. Here's why it matters.

Polyrizon's novel hydrogel shows it can stick to nasal tissue longer without slowing drug delivery, a key innovation in the fight against opioid overdose.

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.

Beyond a simple acquisition, ZenaTech is executing a bold strategy to digitize the American West, transforming old-guard industries with a DaaS network.

In the heart of oil country, a new boom is taking shape. New Era Energy & Digital is building a gigawatt-scale AI campus, but can it win the infrastructure race?

byNordic Acquisition Corp. buys another month in its search for a Nordic tech merger, but each extension drains funds and tests investor patience.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

How TerraVest's aggressive acquisition spree is reshaping industrial markets and delivering substantial returns to shareholders. Dive into the strategy.

Nasdaq-listed Caliber moves beyond passive holding, staking 75,000 LINK to actively generate yield. A look at the high-stakes strategy bridging Wall Street and Web3.

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

By replacing spreadsheets with a cloud platform, New Mexico created a 4.25x funding multiplier, setting a new standard for government efficiency.